- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04227379
Diabetes Disparities: Texting to Extend Treatment (DD-TXT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type 2 Diabetes is a common, complex health condition which can result in many serious and costly health complications if not treated and controlled properly. One in four Veterans are diagnosed with Type 2 Diabetes. Vulnerable Veterans, such as minority, low-income, or rural Veterans, and Veterans with comorbid mental health diagnoses, are disproportionately affected and are less likely to have their diabetes under control. The goal of this study, using a randomized comparative effectiveness design, is to test the comparative effectiveness of an interactive, tailored self-management texting protocol (DD-TXT), versus a traditional education-only intervention (DSE) in a sample of Veterans with uncontrolled diabetes.
The investigators will recruit from Veterans age 18 years and above who are actively receiving care at the study sites (as determined by upcoming scheduled appointment) who have uncontrolled glucose (HbA1c >= 8.0% for at least 50% of the most recent 6 months). Participants who meet these conditions and enroll in the study will be randomized to one of two groups. Those randomized to the intervention group will receive text messages from the DD-TXT protocol for 6 months, and those in the comparison group will receive text messages from DSE, a diabetes skills education-only texting protocol, for 6 months. The primary outcome will be HbA1c percent time in control. Secondary outcomes include self-reported adherence to diabetes self-care recommendations (SCI-R), diabetes self-efficacy, diabetes distress, LDL, and blood pressure control. The investigators hypothesize that DD-TXT will result in better proximal health outcomes and diabetes self-management behaviors vs an education-only protocol (DSE).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stephanie L Shimada, PhD
- Phone Number: (781) 687-2208
- Email: Stephanie.Shimada@va.gov
Study Contact Backup
- Name: Timothy P Hogan, PhD MS BS
- Phone Number: (781) 687-3181
- Email: timothy.hogan@va.gov
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608-1135
- Enrolling by invitation
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Enrolling by invitation
- Jesse Brown VA Medical Center, Chicago, IL
-
-
Massachusetts
-
Bedford, Massachusetts, United States, 01730-1114
- Recruiting
- VA Bedford HealthCare System, Bedford, MA
-
Contact:
- John M Wells, PhD
- Phone Number: 781-687-2924
- Email: John.Wells5@va.gov
-
Principal Investigator:
- Stephanie L Shimada, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Veterans
- active VHA patients with type 2 diabetes
- have had at least 4 VA outpatient encounters in the previous year
- have a future appointment scheduled, and not be hospitalized or institutionalized or have participated in Aim 1 DD-TXT development
- must have access to their own or a cohabiting family member's cell phone or smartphone for participation. --must be willing and able to text, not have any visual impairment that would prevent them from reading or replying to text messages, and must be cognitively capable of consent to participate.
- must also have HbA1c lab data (2+ values) for the 12 months prior to RCT recruitment.
- must have inadequate glycemic control for at least 50% of the 6 months before enrollment.
Exclusion Criteria:
-Non-Veterans
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DD-TXT
Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT).
The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g.
nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
|
Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT).
The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g.
nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
|
Active Comparator: DSE
The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE).
DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled "Self-Care Skills for the Person with Diabetes", which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care.
Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message.
There will be no customizable or interactive content for the DSE arm.
|
The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE).
DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled "Self-Care Skills for the Person with Diabetes", which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care.
Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from workbook content but shortened to fit the 160-character limit of a text message (See Appendix 3 for sample messages from workbook).
There will be no customizable or interactive content for the DSE arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c percent time in control
Time Frame: 6 month follow up
|
The investigators will examine the changes in HbA1c percent time in control.
These data will be calculated using HbA1c measures pulled from the electronic medical record data.
|
6 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
self-reported adherence to diabetes self-care recommendations (SCI-R)
Time Frame: 6 month follow up
|
Secondary outcomes include self-reported adherence to diabetes self-care recommendations (SCI-R).
These will be collected from the patient via a questionnaire conducted over the phone.
|
6 month follow up
|
LDL
Time Frame: 6 month follow up
|
Secondary outcomes include LDL.
These data will be pulled from the electronic medical record data.
|
6 month follow up
|
self-reported diabetes self-efficacy
Time Frame: 6 month follow up
|
Secondary outcomes include self-reported adherence to diabetes self-efficacy.
These will be collected from the patient via a questionnaire conducted over the phone.
|
6 month follow up
|
self-reported diabetes distress
Time Frame: 6 month follow up
|
Secondary outcomes include self-reported diabetes distress.
These will be collected from the patient via a questionnaire conducted over the phone.
|
6 month follow up
|
blood pressure control
Time Frame: 6 month follow up
|
Secondary outcomes include blood pressure control.
These data will be pulled from the electronic medical record data.
|
6 month follow up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephanie L Shimada, PhD, VA Bedford HealthCare System, Bedford, MA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIR 17-087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Intervention 1- DD-TXT
-
Northwestern UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedDepression | Postpartum Depression | Perinatal DepressionUnited States
-
Alcon ResearchCompletedRefractive Errors | MyopiaUnited States
-
Coopervision, Inc.CompletedMyopiaUnited States
-
Thomas Jefferson UniversityRecruitingErectile Dysfunction | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8United States
-
Texas State UniversityKansas State University; Penn State UniversityUnknownRomantic Relationship Skills | Coparenting Skills
-
Arkansas Children's Hospital Research InstituteRecruiting
-
Hospital Universitario Central de AsturiasRecruiting
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity of Vienna; University of Helsinki; Aalto University; Firstbeat Technologies... and other collaboratorsCompleted
-
British Columbia Cancer AgencyGenomic Health®, Inc.Not yet recruiting
-
Medical University of LodzNational Science Centre, PolandCompletedChronic Obstructive Pulmonary Disease (COPD)Poland